CDK4-IN-1

CAS No. 1256963-02-6

CDK4-IN-1 ( LEE011 analog; CDK4-IN-1; CDK4IN-1; CDK4-IN1 )

Catalog No. M11055 CAS No. 1256963-02-6

CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM.

Purity : >98%(HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 873 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    CDK4-IN-1
  • Note
    Research use only, not for human use.
  • Brief Description
    CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM.
  • Description
    CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM; 1500 and 500 fold than CDK1/Cyclin B (IC50>15 uM) and CDK2/Cyclin A (IC50=5.265 uM) respectively.
  • Synonyms
    LEE011 analog; CDK4-IN-1; CDK4IN-1; CDK4-IN1
  • Pathway
    Angiogenesis
  • Target
    CDK
  • Recptor
    CDK4; Cyclin D1
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1256963-02-6
  • Formula Weight
    440.97
  • Molecular Formula
    C22H29ClN8
  • Purity
    >98%(HPLC)
  • Solubility
    DMSO: 10 mM
  • SMILES
    CN(C1CCN(C2=CN=C(NC3=NC=CC(C4=C(C(C)C)NN=C4Cl)=N3)C=C2)CC1)C
  • Chemical Name
    4-(3-Chloro-5-propan-2-yl-1H-pyrazol-4-yl)-N-[5-[4-(dimethylamino)piperidin-1-yl]pyridin-2-yl]pyrimidin-2-amine

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Cho YS, et al. J Med Chem. 2010 Nov 25;53(22):7938-57.
molnova catalog
related products
  • 4-Methoxybenzoic aci...

    4-Methoxybenzoic acid could be used as raw material in cosmetic and dermatologic products and/or aroma components in foodstuffs, it has antiinflammatory and antimicrobial activities.

  • Kenpaullone

    Kenpaullone (9-Bromopaullone,NSC-664704) is a potent inhibitor of CDK1/cyclin B with IC50 of 0.4 uM, also inhibited CDK2/cyclin A (IC50=0.68 uM), CDK2/cyclin E (IC50-7.5 uM) and CDK5/p25 (IC50=0.85 uM).

  • VMY-1-103

    A novel dansylated analog of purvalanol B, and a CDK inhibitor that inhibits cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B.